Ironwood Pharmaceuticals IRWD Restructuring Expense Benefit
Restructuring Expense Benefit at other companies
Other financials
Where this comes from
Reported directly by Ironwood Pharmaceuticals in its filing.
Tagged under the XBRL concept irwd:RestructuringExpenseBenefit.
The official record: Ironwood Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ironwood Pharmaceuticals's restructuring expense benefit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ironwood Pharmaceuticals's restructuring expense benefit?
- Ironwood Pharmaceuticals (IRWD) reported restructuring expense benefit of -$40K in Q1 2026.
- How has Ironwood Pharmaceuticals's restructuring expense benefit changed year-over-year?
- Ironwood Pharmaceuticals's restructuring expense benefit decreased by 100.2% year-over-year, from $18.56M to -$40K.
- What is the long-term trend for Ironwood Pharmaceuticals's restructuring expense benefit?
- Over 3 years (2021 to 2025), Ironwood Pharmaceuticals's restructuring expense benefit has grown at a 675.3% compound annual growth rate (CAGR), from -$44K to $20.51M.
- What does restructuring expense benefit mean?
- This metric represents the net financial impact of organizational restructuring activities, including severance costs, facility closures, or asset impairments. It reflects the accounting gain or expense recognized when a company streamlines operations to improve long-term efficiency. Investors monitor this to distinguish between core operational performance and non-recurring charges related to corporate transformation.